Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

C4 Therapeutics Q3 EPS $(0.44) Misses $(0.40) Estimate, Sales $11.230M Beat $6.280M Estimate

Author: Benzinga Newsdesk | November 06, 2025 07:10am
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.40) by 10.28 percent. This is a 25.71 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $11.230 million which beat the analyst consensus estimate of $6.280 million by 78.82 percent. This is a 26.90 percent decrease over sales of $15.362 million the same period last year.

Posted In: CCCC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist